Odyssey Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Odyssey Therapeutics Inc. (Nasdaq: ODTX) is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from serious autoimmune and inflammatory diseases, with a secondary focus on oncology. The company leverages an integrated drug discovery platform combining machine learning, structural biology, and advanced chemistry to target upstream signaling nodes in the innate immune system. By utilizing a modality-agnostic approach, Odyssey designs highly selective small molecules and protein therapeutics to block pathological inflammatory cascades, aiming to achieve deep and durable clinical remission where standard-of-care therapies fall short.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing OD-001, an oral small-molecule RIPK2 scaffolding inhibitor, into broader clinical trials for moderate-to-severe ulcerative colitis, including a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab.
Expected impact: To establish OD-001 as a highly effective, well-tolerated oral treatment option that targets upstream inflammatory pathways rather than single downstream cytokines.
Developing a robust pipeline of precision immunomodulators, including OD-002 (an SLC15A4 inhibitor targeting pathogenic B cells and interferon signaling) and OD-003 (a TNFR2 agonist protein designed to expand regulatory T cells).
Expected impact: To diversify the clinical portfolio and address significant unmet needs in lupus, Sjögren's syndrome, and other autoimmune diseases.
Integrating quantum machine learning, computational chemistry, and structural biology to rapidly identify and optimize novel therapeutics against difficult-to-drug targets, such as transcription factors.
Expected impact: To accelerate lead identification and optimization, reduce prediction errors, and lower the volume of experimental data required to generate high-quality drug candidates.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Rahko's quantum machine learning drug discovery platform, combining physics-based molecular simulation and machine learning with Odyssey's drug-hunting expertise to accelerate lead identification and address the undruggable genome.
Financial impact: The transaction terms included potential contingent milestone payments of up to $30.0 million to the former shareholders of Rahko.
Strategic Partnerships
To jointly discover and optimize small-molecule medicines against select therapeutic targets by combining AI, machine learning, computational chemistry, and drug discovery expertise.
Terms: Odyssey received an upfront payment and is eligible for milestone payments and royalties.
To jointly discover and develop small-molecule medicines against transcription factor targets of interest, combining Odyssey's immunology and transcription factor biology expertise with Terray's tNova AI platform.
Terms: The parties collaborate to identify development candidates, with Odyssey providing background IP and structural biology know-how for lead maturation.